Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation

• Shiqi Mao,
• Libo Luo,
• Shuo Yang,
• Yan Wang,
• Fei Zhou,
• Jia Yu,
• Bin Chen,
• Guanghui Gao,
• Xuefei Li,
• Chao Zhao,
• Lei Cheng,
• Yiwei Liu,
• Wanying Wang,
• Keyi Jia,
• Chuchu Shao,
• Xinyu Liu,
• Xiaoxia Chen,
• Chunxia Su,
• Caicun Zhou,
• Fengying Wu,
• Shengxiang Ren,
• Xiangxiang Pan,
• Peifang Wei

Affiliations

Shiqi Mao

Libo Luo

Shuo Yang

Yan Wang

Fei Zhou

Jia Yu

Bin Chen

Guanghui Gao

Xuefei Li

Chao Zhao

Lei Cheng

Yiwei Liu

Wanying Wang

Keyi Jia

Chuchu Shao

Xinyu Liu

Xiaoxia Chen

Chunxia Su

Caicun Zhou

Fengying Wu

Shengxiang Ren

Xiangxiang Pan

Peifang Wei